Search
Lurasidone
go.drugbank.com/drugs/DB08815ApprovedInvestigationalIt was approved by the U.S. … Food and Drug Administration (FDA) for treatment of schizophrenia on October 29, 2010 and is currently pending approval for the treatment of bipolar disorder in the United States.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeGefapixant
go.drugbank.com/drugs/DB15097Approved[L48596,L48591] It is the first therapy to be approved for the treatment of RCC or UCC in the EU.[L48601] … [L48596] Gefapixant is a novel antagonist of the P2X3 receptor that works to reduce the cough reflex in patients with chronic cough.
Mitapivat
go.drugbank.com/drugs/DB16236ApprovedInvestigationalIt works to increase the activity of erythrocyte pyruvate kinase, a key enzyme involved in the survival of red blood cells. … Defects in the pyruvate kinase enzyme in various red blood cells disorders lead to the lack of energy production for red blood cells, leading to lifelong premature destruction of red blood cells or chronic
Apixaban
go.drugbank.com/drugs/DB06605ApprovedInvestigationalIt is marketed under the name Eliquis[Label,L6043]. Apixaban was approved by the FDA on December 28, 2012[L6043]. … Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic
Lenacapavir
go.drugbank.com/drugs/DB15673ApprovedInvestigational[A244170, A244175, A244180, A244190] Lenacapavir was first globally approved on August 22, 2022 by the European Commission to treat adults with multi-drug resistant HIV infection. … HIV/AIDS remains an area of concern despite the introduction of numerous successful therapies, mainly due to the emergence of multidrug resistance and patient difficulty in adhering to treatment regimens
Dosulepin
go.drugbank.com/drugs/DB09167ApprovedInvestigationalDosulepin inhibits the reuptake of biogenic amines, increasing available neurotransmitter levels at the synaptic cleft. … The use of dosulepsin is only recommended in patients who are intolerant or unresponsive to alternative antidepressant therapies.
Synonyms: (3E)-3-dibenzo[b,e]thiepin-11(6H)-ylidene-N,N-dimethylpropan-1-amine, 11-(3-Dimethylaminopropylidene)-6,11-dihydrodibenzo(b,e)thiepinCategories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeAbametapir
go.drugbank.com/drugs/DB11932Approvedhelp to curb the development of resistance to this agent. … first to kill newly hatched lice that resisted the initial treatment.
Ioversol
go.drugbank.com/drugs/DB09134ApprovedInvestigational[L41790] The intravascular administration of iodine compounds, such as ioversol, enhances the contrast between vessels in the path of the flow of the contrast medium and normal tissue, allowing the visualization … [L41780] Iodine has a high atomic density, which gives it the ability to attenuate X-rays.
Mesalazine
go.drugbank.com/drugs/DB00244ApprovedInvestigationalIn the present day, contemporary research regarding novel methods to stabilize mesalazine continues and interest in the agent's capacity to decrease inflammatory activity and subsequently potentially reduce … Throughout the late seventies and the eighties, important research initiatives developed stable mesalazine formulations like the eudragit-S coating of Asacol brand mesalazine and the Pentasa brand's encapsulation
Products: MELAZ 500 MG TABLETA DE LIBERACION RETARDADA, PENTASA®1 G GRANULOS DE LIBERACION PROLONGADAIvabradine
go.drugbank.com/drugs/DB09083ApprovedInvestigationalIvabradine acts by selectively inhibiting the "funny" channel pacemaker current (If) in the sinoatrial node in a dose-dependent fashion, resulting in a lower heart rate and thus more blood to flow to the … Ivabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus rhythm with resting heart rate